

Supplementary Materials for

Aloe-emodin prevents nerve injury and neuroinflammation caused by ischemic stroke via PI3K/AKT/mTOR and NF- κ B pathway

Minghua Xian^{†1,2,3}, Jiale Cai^{†1,2,3}, Kening Zheng^{1,2,3}, Qu Liu^{1,2,3}, Yali Liu^{1,2,3}, Huiting Lin^{1,2,3}, Shengwang Liang^{*1,2,3}, Shumei Wang^{*2,3,4}

1 School of Traditional Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou 510006, China

2 Key Laboratory of Digital Quality Evaluation of Chinese Materia Medica of State Administration of TCM, Guangzhou 510006, China

3 Engineering & Technology Research Center for Chinese Materia Medica Quality of the Universities of Guangdong Province, Guangzhou 510006, China

4 School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, China

† These authors contributed equally to this work.

* Correspondence: Shumei Wang, E-mail: gdpwsm@126.com, Tel.:020-39352177; Shengwang Liang, E-mail: swliang371@163.com, Tel.:020-39352177

This WORD file includes:

Figures. 1 to 6 and Table 1




Fig1 Neuroprotective effect of AE. (A) Evaluation of neurological impairment after different conditions. **(B)** Grasping experiment score after different conditions. ## $P < 0.01$ compared with sham group; * $P < 0.05$, ** $P < 0.01$ compared with the I/R group.




Fig 2 The first-order mass spectrogram of AE.




Fig 3 The secondary mass spectrogram of AE.




Fig 4 The standard curve of AE content in brain tissue.




Fig 5 The standard curve of AE content in plasma tissue.




Fig 6. Effect of AE on OGD/R injury morphology of SH-SY5Y cells (10 × 10 times). (A) Control group. (B) model group. (C) Edaravone group. (D) AE group (10μmol/L). (E) AE group (8μmol/L). (F) AE group (6μmol/L).

Table 1 Survival rate of SHSY5Y cells under different conditions.

Na ₂ S ₂ O ₄ (mmol/L)	Cell survival rate (%)		
	1h	2h	4h
0	100.00±3.10	100.00±6.59	100.00±5.03
1	87.13±1.97 ^{##}	63.75±3.57 ^{##}	64.67±4.27 ^{##}
5	81.56±2.82 ^{##}	62.75±3.14 ^{##}	62.88±3.40 ^{##}
10	74.73±3.91 ^{##}	53.72±2.39 ^{##}	39.12±3.17 ^{##}
15	74.45±1.88 ^{##}	41.37±5.22 ^{##}	31.23±2.54 ^{##}
20	71.94±2.71 ^{##}	37.35±6.32 ^{##}	21.97±2.16 ^{##}
30	49.18±5.90 ^{##}	22.02±3.21 ^{##}	17.51±1.33 ^{##}
40	38.10±2.46 ^{##}	16.36±2.40 ^{##}	14.47±2.95 ^{##}

vs control group, ^{##}*P* < 0.01